Cytokinetics faces shareholder investigation amid FDA review delay
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17 Dec 25
Source: Coinmarketcap
Cytokinetics Inc's stock price fell by 4.03% as it hit a 20-day low, reflecting a challenging market environment.
The decline is attributed to a shareholder investigation initiated by Grabar Law Office regarding misleading statements made by Cytokinetics' executives, which may expose the company to legal liabilities. Additionally, the FDA has postponed the review date for its New Drug Application for aficamten, further impacting investor confidence and market trust.
This situation raises concerns about the company's reputation and future financing, as the ongoing investigation and regulatory delays could hinder its growth prospects and investor sentiment.
Analyst Views on CYTK
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 89.33 USD with a low forecast of 61.00 USD and a high forecast of 136.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 64.010
Low
61.00
Averages
89.33
High
136.00
Current: 64.010
Low
61.00
Averages
89.33
High
136.00
About CYTK
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
